Personalized medicine — linking therapies to molecular diagnostic tests to ensure that the right treatments are targeted to the right patients — is still more aspiration than reality.
Although we have made enormous progress in developing a new scientific appreciation of human heterogeneity, as evidenced by the rise in the number of personalized treatments on the market from five in 2008 to over 250 today, significant obstacles remain. In brief, we need more evidence that personalized medicine works — that it can improve clinical outcomes while making health care more efficient and therefore less costly. We also need to understand the opportunities and challenges shaping the pace of our progress toward integrating personalized medicine into clinical work streams.
PMC's research program is focused on evaluating technological progress in personalized medicine, assessing its clinical and economic value, and examining clinical integration efforts.
Understanding and Delivering the Clinical and Economic Benefits of Personalized Medicine: A Research Program Focused on Evaluating Technological Progress, Assessing Clinical and Economic Value, and Examining Clinical Integration Strategies
Daryl Pritchard, Ph.D., Senior Vice President, Science Policy
Lindsay Stephens, Program Manager & Secretary to the Board